# Weight-Based Torsemide Dosing in Subjects With Heart Failure

> **NCT03187509** · PHASE4 · COMPLETED · sponsor: **New York City Health and Hospitals Corporation** · enrollment: 52 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Torsemide
- **OTHER:** Standard Outpatient Heart Failure Management

## Key facts

- **NCT ID:** NCT03187509
- **Lead sponsor:** New York City Health and Hospitals Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-17
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-03-14
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187509, "Weight-Based Torsemide Dosing in Subjects With Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03187509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*